

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5678367

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
UNIVERSITY MEDICAL CENTER HAMBURG-EPPENDORF	08/01/2018
RECEIVING PARTY DATA	
Name:	NEUTROLIS THERAPEUTICS, INC.
Street Address:	700 MAIN STREET, NORTH
Internal Address:	CAMBRIDGE
City:	MASSACHUSETTS
State/Country:	UNITED STATES
Postal Code:	02139
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	16530141
PCT Number:	US2018047084
CORRESPONDENCE DATA	
Fax Number:	(202)739-3001
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	617-951-8440
Email:	patents@morganlewis.com, penny.coelho@morganlewis.com
Correspondent Name:	MARK L. HAYMAN
Address Line 1:	MORGAN, LEWIS & BOCKIUS LLP
Address Line 2:	1111 PENNSYLVANIA AVE, N.W.
Address Line 4:	WASHINGTON, D.C. 20004
ATTORNEY DOCKET NUMBER:	NTR-001US&PC/119601-5001
NAME OF SUBMITTER:	MARK L. HAYMAN
SIGNATURE:	/MARK L. HAYMAN/
DATE SIGNED:	08/20/2019
Total Attachments: 2	
source=Short Form Assignment - signed - 180801#page1.tif	
source=Short Form Assignment - signed - 180801#page2.tif	

PATENT ASSIGNMENT

This Patent Assignment is made between the University Medical Center Hamburg-Eppendorf, having its principal office at Martinistr. 52, D-20246 Hamburg, Germany ("**Assignor**"), and Neutrolis Therapeutics, Inc., a corporation having its principal office at 700 Main Street North, Cambridge MA 02139 ("**Assignee**").

WHEREAS, Assignor and Assignee are parties to that certain Patent Assignment and Transfer Agreement with an Effective Date of July 11, 2018, in which Assignor agreed to assign certain patent rights to Assignee for good and valuable consideration.


Assignor hereby confirms assignment of the following patent rights to Assignee ("the Patent Rights"):

Assignor Ref.	Title	Country /Application No.	Filing Date
UKE 280	ENGINEERED DNASE ENZYMES AND USE IN THERAPY	US 62/547,220	August 18, 2017
UKE 280	ENGINEERED DNASE ENZYMES AND USE IN THERAPY	US 62/611,166	December 28, 2017
UKE 260	PHARMACEUTICAL PREPARATION FOR TREATING OR PREVENTING TISSUE ADHESIONS	EP 17152341.8	January 20, 2017
UKE 260	PHARMACEUTICAL PREPARATION FOR TREATING OR PREVENTING TISSUE ADHESIONS	PCT/EP2018/051444	January 22, 2018
UKE 267	ANIMAL MODEL FOR DRUG DEVELOPMENT	EP 17152528.0	January 20, 2017
UKE 267	ANIMAL MODEL FOR DRUG DEVELOPMENT	EP 17194478.8	October 2, 2017
UKE 267	ANIMAL MODEL FOR DRUG DEVELOPMENT	PCT/EP2018/051488	January 22, 2018

Assignor hereby assigns, transfers, and conveys to Assignee and its successors and assigns, Assignor's right, title, and interest in and to the Patent Rights, which shall include all divisions, continuations, or continuations-in-part thereof, and all patents issuing thereon including reissues, renewals, substitutions, re-examinations and extensions thereof, and any and all corresponding foreign patents and patent applications; and all rights and privileges pertaining to the Patent Rights, including, without limitation, all causes of action, claims, demands presently or hereafter accruing with respect to the same, including the right to sue or bring other actions for past, present and future infringement thereof anywhere in the world. Assignor further assigns all rights, and empowers Assignee, its successors, assigns and nominees, to make applications for patent registration or other intellectual property protection anywhere in the world, to claim and receive the benefit of any applicable rights of priority in connection with such applications, to

prosecute such applications to issue, and to have any and all registrations issued in the name of Assignee for all Patent Rights.


IN THE TESTIMONY WHEREOF, we have hereunto set our signatures on the date indicated below.

University Medical Center Hamburg-
Eppendorf
Universität Hamburg
Universitätsklinikum Hamburg-Eppendorf
By: 
Medizinische Fakultät
Martinistraße 52 20246 Hamburg

Dr. Ralf Krappa / Tina Marschall
Title: on behalf of the Board of Directors

Aug 01, 2018

Neutrolis Therapeutics, Inc.

By: 
Digitally signed by Abdul Hakkim
Rahamathullah
DN: cn=Abdul Hakkim Rahamathullah,
o=Neutrolis, ou,
email=hakkim@neutrolis.com, c=US
Date: 2018.08.01 10:09:13 -0400

Abdul Hakkim Rahamathullah
Title: Co-Founder and CEO